Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of BIBR 1048 MS (Dabigatran Etexilate) in Healthy Males
NCT02170909Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2004
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of dabigatran in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change in vital signs at Day 26, Change in 12-lead electrocardiogram at Day 26 and 2 more. Started Dec 2004; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02170909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170909.